本文關(guān)鍵詞： 牛蒡子苷元 免疫性血小板減少 動(dòng)物模型 調(diào)節(jié)性T細(xì)胞　出處：《沈陽藥科大學(xué)學(xué)報(bào)》2015年04期 　論文類型：期刊論文

【摘要】：目的考察牛蒡子苷元對(duì)免疫性血小板減少疾病(immune thrombocytopenic purpura,ITP)動(dòng)物模型的藥效學(xué),并初步研究其作用機(jī)制。方法采用SD大鼠腹腔注射兔抗大鼠血小板(platelet,PLT)抗體血清制備被動(dòng)型ITP動(dòng)物模型,Balb/c小鼠腹腔注射大鼠血小板抗原制備小鼠交叉免疫反應(yīng)型ITP模型,SD大鼠皮下注射環(huán)磷酰胺制備大鼠藥物誘導(dǎo)型血小板減少模型,通過血細(xì)胞計(jì)數(shù)儀檢測(cè)以上3種動(dòng)物模型全血PLT數(shù)量,并研究牛蒡子苷元對(duì)ITP模型的藥效作用;正常Balb/c小鼠給予牛蒡子苷元1.0 mg·kg-1·d-1后,利用流式技術(shù)檢測(cè)脾臟淋巴細(xì)胞Treg細(xì)胞比率,研究牛蒡子苷元藥理作用機(jī)制。結(jié)果成功構(gòu)建3種ITP模型,牛蒡子苷元能顯著性提高被動(dòng)型ITP模型與交叉免疫反應(yīng)型ITP模型的PLT數(shù)量,與模型組相比有顯著性差異(P0.05);對(duì)環(huán)磷酰胺造成的模型作用不明顯(P0.05);牛蒡子苷元能顯著性提高正常小鼠脾臟淋巴細(xì)胞Treg細(xì)胞比率(P0.05)。結(jié)論牛蒡子苷元對(duì)免疫性血小板減少動(dòng)物模型取得較好的治療效果,這可能與其升高Treg細(xì)胞比率有關(guān)。
[Abstract]:Objective to investigate the pharmacodynamics of arctiin on immune thrombocytopenic purpura (thrombocytopenic) model of immune thrombocytopenia. Methods the passive ITP animal model was established by intraperitoneal injection of rabbit anti-platelet platelet (PLT) antibody serum from SD rats. Balb/c mice were injected intraperitoneally with rat platelet antigen to establish cross-immunoreactive ITP model and SD rats were subcutaneously injected with cyclophosphamide to prepare drug-induced thrombocytopenia model. The whole blood PLT of the above three animal models was detected by blood cell counter, and the effect of arctiin on ITP model was studied. The ratio of Treg cells in spleen lymphocytes was detected by flow cytometry after normal Balb/c mice were given lappadin 1.0 mg 路kg-1 路d-1. The pharmacological mechanism of arctiin was studied. Results three ITP models were successfully constructed. Arctiin could significantly increase the number of PLT in passive ITP model and cross-immunoreactive ITP model. There was significant difference between the model group and the model group (P 0.05). The effect on the model caused by cyclophosphamide was not obvious (P 0.05). Arctigenin can significantly increase the ratio of Treg cells in spleen lymphocytes of normal mice (P 0.05). Conclusion Arctigenin has a good therapeutic effect on immune thrombocytopenia animal model. This may be related to its increased Treg cell ratio.
【作者單位】： 沈陽藥科大學(xué)生命科學(xué)與生物制藥學(xué)院;魯南制藥集團(tuán)藥理中心;
【分類號(hào)】：R285.5;R-332
【正文快照】： 免疫性血小板減少(immune thrombocytopenicpurpura,ITP)是常見的以凝血障礙為特征的自身免疫性疾病,臨床治療以口服糖皮質(zhì)激素與靜脈注射免疫球蛋白為主要方法。ITP為慢性病,長(zhǎng)期口服激素治療副作用大,注射免疫球蛋白費(fèi)用高[1-2],因此從祖國傳統(tǒng)醫(yī)學(xué)尋找治療藥物具有重要意義

【參考文獻(xiàn)】

相關(guān)期刊論文 前6條

1 聶紅;李孔燕;張曉琦;馮雪瑩;楊端容;吳玉斯;周玖瑤;葉文才;;環(huán)磷酰胺誘導(dǎo)小鼠血小板減少癥模型的建立(英文)[J];動(dòng)物學(xué)研究;2009年06期

2 張愛梅;徐修才;王寧玲;張翠萍;沈元元;李慶;鄔志偉;王會(huì)平;翟志敏;;CD4~+CD25~+Treg在兒童急性免疫性血小板減少性紫癜發(fā)病機(jī)制中的作用[J];臨床兒科雜志;2009年12期

3 瞿文;伍星;王s，

本文編號(hào)：1456667